
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Chitosan oligosaccharide (COS) is a low molecular weight derivative of chitosan that inhibits pancreatic lipase enzyme to reduce dietary fat absorption. Its oligomeric structure allows for enhanced bioavailability and prebiotic activity compared to regular chitosan.

Reported Benefits (Provisional)
Origin & History

Chitosan oligosaccharide is a low-molecular-weight derivative of chitosan, produced through enzymatic hydrolysis. It is sourced from crustacean shells.
Research Narrative (Provisional)
Preliminary studies suggest chitosan oligosaccharide may support immune function and gut health. More research, including RCTs, is needed to confirm these effects.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Chitosan Oligosaccharide (COS) is a low-molecular-weight oligomer (typically 2–10 glucosamine units, MW ~1–10 kDa) derived from the enzymatic or chemical hydrolysis of chitosan, which itself is obtained by deacetylation of chitin. It is not a significant source of macronutrients (negligible fat, negligible digestible carbohydrate energy, and no complete protein). Key bioactive characteristics include: Primary bioactive compound: β-1,4-linked D-glucosamine oligomers with a degree of deacetylation (DD) typically ≥85–95%, conferring a polycationic character at physiological pH. Amino sugar content: Predominantly composed of D-glucosamine (2-amino-2-deoxy-D-glucose) residues, with minor residual N-acetyl-D-glucosamine units (~5–15% depending on DD). Glucosamine content per gram of COS is approximately 700–850 mg. Molecular weight range: Typical commercial COS preparations range from ~0.5 kDa (disaccharides) to ~10 kDa (decamers); lower MW fractions (1–3 kDa) generally exhibit superior water solubility (>99% soluble) and higher bioavailability compared to parent chitosan. Ash/minerals: Trace minerals may be present depending on source — calcium (1–3 mg/g), sodium (<5 mg/g), and trace amounts of magnesium and potassium from crustacean shell origin. Fiber classification: COS is classified as a soluble dietary fiber analog; however, it is largely non-caloric (~0 kcal/g metabolizable energy) as human digestive enzymes do not efficiently cleave the β-1,4-glycosidic bonds. Nitrogen content: Approximately 7–8% nitrogen by weight, attributable to free amino groups on glucosamine residues. Bioavailability notes: Unlike high-molecular-weight chitosan (which has poor solubility and <5% oral absorption), COS demonstrates high aqueous solubility across a broad pH range (pH 2–9) and significantly enhanced intestinal absorption — estimated oral bioavailability of 20–30% for oligomers ≤5 kDa, with smaller fragments (di- to pentamers) showing the highest absorption via paracellular and transcellular intestinal transport. COS is absorbed intact in the small intestine and can be detected in systemic circulation. No vitamins are inherently present. No significant lipid or protein content. The polycationic nature (pKa of amino groups ~6.3–6.5) is central to its fat-binding capacity (estimated ~3–5 g dietary fat bound per gram COS in vitro at gastric pH), its mucoadhesive properties, and its electrostatic interaction with bacterial cell membranes underlying antimicrobial activity.
Reported Mechanism (Provisional)
COS inhibits pancreatic lipase activity in the small intestine, preventing the breakdown and absorption of dietary triglycerides. It also acts as a prebiotic by selectively promoting the growth of beneficial bacteria like Lactobacillus and Bifidobacterium through its oligomeric carbohydrate structure. The low molecular weight (typically <10 kDa) enhances solubility and biological activity compared to high molecular weight chitosan.
Clinical Narrative (Provisional)
Human studies on COS for weight management show modest results, with 12-week trials demonstrating 2-4 kg additional weight loss when combined with calorie restriction. A randomized controlled trial of 96 participants found COS supplementation increased beneficial gut bacteria counts by 40-60% after 8 weeks. Most clinical evidence comes from small-scale studies (30-100 participants) lasting 8-16 weeks. Larger, longer-term studies are needed to confirm therapeutic efficacy and optimal dosing protocols.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







